Invention Grant
- Patent Title: Dual mechanism inhibitors for the treatment of disease
-
Application No.: US16730058Application Date: 2019-12-30
-
Publication No.: US11028081B2Publication Date: 2021-06-08
- Inventor: Mitchell A. deLong , Jill Marie Sturdivant , Susan M. Royalty
- Applicant: Aerie Pharmaceuticals, Inc.
- Applicant Address: US NJ Bedminster
- Assignee: Aerie Pharmaceuticals, Inc.
- Current Assignee: Aerie Pharmaceuticals, Inc.
- Current Assignee Address: US NJ Bedminster
- Agency: K&L Gates LLP
- Agent Louis C. Cullman; Benjamin D. Heuberger
- Main IPC: C07D417/12
- IPC: C07D417/12 ; C07C237/20 ; C07D401/12 ; C07D409/12 ; C07D217/00 ; C07C237/42 ; C07D333/40 ; C07D217/04 ; C07D217/02 ; C07D217/22 ; C07D217/24 ; C07D405/12 ; C07D413/12 ; C07D333/38
Abstract:
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Information query
